The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL
The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL
Key insights from lung cancer research at ASCO 2025
POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma
ASCO 2025: Importance of early testing in metastatic prostate cancer
Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer
HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC
New MOAs in prostate cancer treatment - what’s next?
Social determinants and survival outcomes in early-onset colorectal cancer in the US
Low frequency of dihydropyrimidine dehydrogenase variants in Mexican GI cancers should induce testing guideline reform
Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy
GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics
Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery